Quanterix Announces Landmark Nature Study Redefining Alzheimer's Disease Neuropathology Prevalence

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Quanterix Corporation Announces Date of 2026 Annual Meeting
Quanterix Releases Financial Results for the Fourth Quarter and Full Year 2025
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
Quanterix to Participate in Upcoming Investor Conferences
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection
Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer's Risk Profiling
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.